Sanara MedTech (SMTI) awards COO 13,956 restricted shares

Rhea-AI Filing Summary

Waldrop Jacob A. reported acquisition or exercise transactions in this Form 4 filing.

Sanara MedTech Inc. reported that Chief Operating Officer Jacob A. Waldrop received a grant of 13,956 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this equity award, his direct holdings total 24,755 shares of common stock.

The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22 of 2027, 2028 and 2029, provided he remains employed by Sanara MedTech through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Waldrop Jacob A.

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	13,956	$0.00	--

Holdings After Transaction: Common Stock — 24,755 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waldrop Jacob A.

(Last) (First) (Middle)

1200 SUMMIT AVE

SUITE 414

(Street)

FORT WORTH TEXAS 76102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sanara MedTech Inc. [ SMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/22/2026		A		13,956(1)	D	$0(1)	24,755	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date.

	/s/ Jacob A. Waldrop	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Sanara MedTech (SMTI) COO Jacob Waldrop report?

Jacob A. Waldrop, COO of Sanara MedTech, reported receiving a grant of 13,956 restricted shares of common stock. The award was made at no cash cost to him as executive compensation under the company’s 2024 Omnibus Long-Term Incentive Plan, increasing his direct holdings.

How many Sanara MedTech (SMTI) shares does the COO hold after this Form 4?

After the reported grant, COO Jacob A. Waldrop directly holds 24,755 shares of Sanara MedTech common stock. This total reflects the addition of 13,956 restricted shares awarded on March 22, 2026, under the company’s 2024 Omnibus Long-Term Incentive Plan, subject to future vesting conditions.

What are the vesting terms of the 13,956 restricted Sanara MedTech shares?

The 13,956 restricted shares granted to COO Jacob A. Waldrop vest in three equal installments. One-third will vest on March 22, 2027, another third on March 22, 2028, and the final third on March 22, 2029, if he remains employed through each date.

Is the Sanara MedTech COO Form 4 a stock purchase or a compensation grant?

The Form 4 reflects a compensation grant, not a market purchase. Jacob A. Waldrop received 13,956 shares of restricted common stock at a stated price of zero, characterized as a grant or award under Sanara MedTech’s 2024 Omnibus Long-Term Incentive Plan for executives.

Under which plan were the restricted shares to Sanara MedTech COO granted?

The restricted stock granted to COO Jacob A. Waldrop was issued under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. This plan provides equity-based awards, and in this case delivered 13,956 restricted shares with multi-year vesting tied to continued employment at the company.

What conditions must be met for the COO’s Sanara MedTech restricted stock to vest?

For each one-third tranche of the 13,956 restricted shares to vest, Jacob A. Waldrop must remain employed by Sanara MedTech through March 22, 2027, 2028 and 2029, respectively. Continued service on each specified date is the key condition for earning the corresponding vested shares.